Evidence map›Paper›PMID 38507675›Full record

ArticleNeurology2024

Burden of Neurologic Health Care and Incident Neurologic Diagnoses in the Year After COVID-19 or Influenza Hospitalization.

Adam de Havenon, Brian C Callaghan, Yunshan Xu, Maria Connor, Chloe E Hill, John Ney, Gregory J Esper

Abstract read
In one paragraph

Article in Neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Ten Years ofNeurology(R) neuroimmunology & neuroinflammation · 2025
    Article
  7. Update: Protective and risk factors for Parkinson disease.Parkinsonism & related disorders · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Adam de HavenonFrom the Department of Neurology (A.H., Y.X.), Yale University, New Haven, CT; Department of Neurology (B.C.C., C.E.H.), University of Michigan, Ann Arbor; TriNetX (M.C.), Cambridge, MA; Boston University (J.N.), MA; Emory University (G.J.E.), Atlanta, GA.ORCID 0000-0001-8178-8597
Brian C CallaghanFrom the Department of Neurology (A.H., Y.X.), Yale University, New Haven, CT; Department of Neurology (B.C.C., C.E.H.), University of Michigan, Ann Arbor; TriNetX (M.C.), Cambridge, MA; Boston University (J.N.), MA; Emory University (G.J.E.), Atlanta, GA.ORCID 0000-0002-8885-6748
Yunshan XuFrom the Department of Neurology (A.H., Y.X.), Yale University, New Haven, CT; Department of Neurology (B.C.C., C.E.H.), University of Michigan, Ann Arbor; TriNetX (M.C.), Cambridge, MA; Boston University (J.N.), MA; Emory University (G.J.E.), Atlanta, GA.
Maria ConnorFrom the Department of Neurology (A.H., Y.X.), Yale University, New Haven, CT; Department of Neurology (B.C.C., C.E.H.), University of Michigan, Ann Arbor; TriNetX (M.C.), Cambridge, MA; Boston University (J.N.), MA; Emory University (G.J.E.), Atlanta, GA.
Chloe E HillFrom the Department of Neurology (A.H., Y.X.), Yale University, New Haven, CT; Department of Neurology (B.C.C., C.E.H.), University of Michigan, Ann Arbor; TriNetX (M.C.), Cambridge, MA; Boston University (J.N.), MA; Emory University (G.J.E.), Atlanta, GA.ORCID 0000-0001-5307-4167
John NeyFrom the Department of Neurology (A.H., Y.X.), Yale University, New Haven, CT; Department of Neurology (B.C.C., C.E.H.), University of Michigan, Ann Arbor; TriNetX (M.C.), Cambridge, MA; Boston University (J.N.), MA; Emory University (G.J.E.), Atlanta, GA.ORCID 0000-0003-3479-6441
Gregory J EsperFrom the Department of Neurology (A.H., Y.X.), Yale University, New Haven, CT; Department of Neurology (B.C.C., C.E.H.), University of Michigan, Ann Arbor; TriNetX (M.C.), Cambridge, MA; Boston University (J.N.), MA; Emory University (G.J.E.), Atlanta, GA.ORCID 0000-0002-9967-2821

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Optimizing Care for Patients with Drug-Resistant EpilepsyK23NS126495 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Chloe E Hill · 2023 to 2026
$881k
NCATS NIH HHS UL1 TR001863NINDS NIH HHS K23 NS126495
6 · The paper itself

Abstract

BACKGROUND AND

objectiveFollowing the outbreak of viral infections from the severe acute respiratory syndrome coronavirus 2 virus in 2019 (coronavirus disease 2019 [COVID-19]), reports emerged of long-term neurologic sequelae in survivors. To better understand the burden of neurologic health care and incident neurologic diagnoses in the year after COVID-19 vs influenza, we performed an analysis of patient-level data from a large collection of electronic health records (EMR).

methodsWe acquired deidentified data from TriNetX, a global health research network providing access to EMR data. We included individuals aged 18 years or older during index event, defined as hospital-based care for COVID-19 (from April 1, 2020, until November 15, 2021) or influenza (from 2016 to 2019). The study outcomes were subsequent health care encounters over the following year for 6 neurologic diagnoses including migraine, epilepsy, stroke, neuropathy, movement disorders, and dementia. We also created a composite of the 6 diagnoses as an incident event, which we call "incident neurologic diagnoses." We performed a 1:1 complete case nearest-neighbor propensity score match on age, sex, race/ethnicity, marital status, US census region patient residence, preindex years of available data, and Elixhauser comorbidity score. We fit time-to-event models and reported hazard ratios for COVID-19 vs influenza infection.

resultsAfter propensity score matching, we had a balanced cohort of 77,272 individuals with COVID-19 and 77,272 individuals with influenza. The mean age was 51.0 ± 19.7 years, 57.7% were female, and 41.5% were White. Compared with patients with influenza, patients with COVID-19 had a lower risk of subsequent care for migraine (HR 0.645, 95% CI 0.604-0.687), epilepsy (HR 0.783, 95% CI 0.727-0.843), neuropathies (HR 0.567, 95% CI 0.532-0.604), movement disorders (HR 0.644, 95% CI 0.598-0.693), stroke (HR 0.904, 95% CI 0.845-0.967), or dementia (HR 0.931, 95% CI 0.870-0.996). Postinfection incident neurologic diagnoses were observed in 2.79% of the COVID-19 cohort vs 4.91% of the influenza cohort (HR 0.618, 95% CI 0.582-0.657). DISCUSSION: Compared with a matched cohort of adults with a hospitalization or emergency department visit for influenza infection, those with COVID-19 had significantly fewer health care encounters for 6 major neurologic diagnoses over a year of follow-up. Furthermore, we found that COVID-19 infection was associated with a lower risk of an incident neurologic diagnosis in the year after infection.

Indexed as

COVID-19DementiaEpilepsyInfluenza, HumanMigraine DisordersMovement DisordersStrokeAdultAgedDelivery of Health CareFemaleHospitalizationHumansMaleMiddle Aged

Identifiers

PMID38507675
PMCPMC11383855

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.